Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Alnylam Pharmace. buy BMO Capital Markets

Alnylam Pharmace.
Start price
€210.70
24.06.24 / 50%
Target price
€218.11
24.06.25
Performance (%)
32.04%
End price
€278.20
25.06.25
Summary
This prediction ended on 25.06.25 with a price of €278.20. The BUY prediction by BMO_Capital_Markets for Alnylam Pharmace. saw massive gains of 32.04%. BMO_Capital_Markets has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. BMO_Capital_Markets has 50% into this prediction

Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.

AI-generated
Performance without dividends (%)
Name 1w 1m 1y
Alnylam Pharmace. 7.220% 7.220% -47.180%
iShares Core DAX® -0,87 % 5,32 % 6,86 %
iShares Nasdaq 100 -0,38 % 1,98 % 25,70 %
iShares Nikkei 225® -1,68 % 1,95 % 41,44 %
iShares S&P 500 -0,65 % 2,07 % 21,40 %

Comments by BMO_Capital_Markets for this prediction

In the thread Alnylam Pharmace. diskutieren
Prediction Buy
Perf. (%) 32.04%
Target price 218.111
Change
Ends at 24.06.25

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $234.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat

BMO Capital Markets 
0
Report Share
24.06.24
In the thread Trading Alnylam Pharmace.
Prediction Buy
Perf. (%) 32.04%
Target price 218.111
Change
Ends at 24.06.25

Die von BMO_Capital_Markets gewählte maximale Laufzeit wurde überschritten

BMO Capital Markets 
0
Report Share
25.06.25

Current prediction by BMO_Capital_Markets for Alnylam Pharmace.

buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€386.00
05.09.25
€402.93
05.09.26
-46.14%
19.08.26

BMO Capital Markets 
05.09.25 50%

Stopped prediction by BMO_Capital_Markets for Alnylam Pharmace.

buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€199.85
19.08.26
€274.72
19.08.27
4.03%
19.08.26

BMO Capital Markets 
19.08.26 50%
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€279.80
24.06.25
€310.57
24.06.26
-8.86%
25.06.26

BMO Capital Markets 
24.06.25 50%
buy
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€141.40
27.03.24
€216.31
27.03.25
74.96%
28.03.25

BMO Capital Markets 
27.03.24 50%